Methods for solid tumor treatment

Patent metadata

Field	Value
Publication number	US-10874660-B2
Application number	US-201916714099-A
Country	US
Kind code	B2
Filing date	Dec 13, 2019
Priority date	Apr 4, 2016
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.

First claim

We claim:

1. A method for reducing existing tumor metastases in a subject having a malignant solid tumor mass and existing tumor metastases, the method comprising administering to the subject an amount effective of a composition comprising taxane particles to reduce the existing tumor metastases, wherein the taxane is selected from the group consisting of paclitaxel and docetaxel, wherein the taxane particles comprise at least 95% by weight taxane or a pharmaceutically acceptable salt thereof, and wherein the taxane particles have a specific surface area (SSA) of at least 18 m 2 /g, wherein the taxane particles include both agglomerated taxane particles and non-agglomerated taxane particles, and wherein the composition is administered via direct injection into the malignant solid tumor mass or the existing tumor metastases.

2. The method of claim 1 , wherein the composition consists of the taxane particles and a pharmaceutically acceptable carrier.

3. The method of claim 2 , wherein the carrier is an aqueous liquid carrier.

4. The method of claim 3 wherein the aqueous liquid carrier is saline.

5. The method of claim 1 , wherein the composition is a suspension.

6. The method of claim 5 , wherein the suspension further comprises a polysorbate, wherein the polysorbate is present in the suspension at a concentration of between about 0.01% v/v and about 1.5% v/v.

7. The method of claim 5 , wherein the taxane is present in the suspension at a concentration of between about 1 mg/ml and about 40 mg/ml.

8. The method of claim 1 , wherein the taxane particles have a SSA of between 18 m 2 /g and about 50 m 2 /g.

9. The method of claim 1 , wherein the taxane particles have a SSA of at least 18 m 2 /g.

10. The method of claim 1 , wherein the taxane particles have a mean particle size number of between about 0.4 μm and about 1.2 μm.

11. The method of claim 1 , wherein the malignant solid tumor mass is selected from the group consisting of sarcomas, carcinomas, and lymphomas, breast tumors, prostate tumors, head and neck tumors, glioblastomas, bladder tumors, pancreatic tumors, liver tumors, ovarian tumors, colorectal tumors, cutaneous, lymphoid, and gastrointestinal tumors.

12. The method of claim 1 , wherein the taxane is paclitaxel, or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the paclitaxel particles have a mean bulk density between about 0.05 g/cm 3 and about 0.12 g/cm 3 .

14. The method of claim 12 , wherein the paclitaxel particles have a SSA of between 18 m 2 /g and about 40 m 2 /g.

15. The method of claim 1 , wherein the taxane is docetaxel, or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the docetaxel particles have a mean bulk density between about 0.05 g/cm 3 and about 0.12 g/cm 3 .

17. The method of claim 15 , wherein the docetaxel particles have a SSA of between 18 m 2 /g and about 50 m 2 /g.

18. The method of claim 1 , wherein the taxane particles have an SSA of between 18 m 2 /g and about 50 m 2 /g, wherein the taxane particles have a mean particle size number of between about 0.4 μm and about 1.2 μm, and wherein the taxane particles have a mean bulk density between about 0.050 g/cm 3 and about 0.12 g/cm 3 .

19. The method of claim 18 , wherein the taxane is docetaxel or a pharmaceutically acceptable salt thereof.

20. The method of claim 18 , wherein the taxane is paclitaxel or a pharmaceutically acceptable salt thereof.

Assignees

• Crititech Inc
• Critltech Inc

Inventors

• Baltezor Mike
• Dizerega Gere
• Decedue Charles
• Campbell Sam
• Mcclorey Matt

Classifications

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K45/00 Primary

  Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title

• A61K33/243

  Platinum; Compounds thereof · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title